Updating the OMERACT filter : implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity
OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) Filter provides guidelines for the development and validation of outcome measures for use in clinical research. The "Truth" section of the OMERACT Filter requires that criteria be met to demonstrate that the outcome instrument meets the criteria for content, face, and construct validity.
METHODS: Discussion groups critically reviewed a variety of ways in which case studies of current OMERACT Working Groups complied with the Truth component of the Filter and what issues remained to be resolved.
RESULTS: The case studies showed that there is broad agreement on criteria for meeting the Truth criteria through demonstration of content, face, and construct validity; however, several issues were identified that the Filter Working Group will need to address.
CONCLUSION: These issues will require resolution to reach consensus on how Truth will be assessed for the proposed Filter 2.0 framework, for instruments to be endorsed by OMERACT.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2014 |
---|---|
Erschienen: |
2014 |
Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
---|---|
Enthalten in: |
The Journal of rheumatology - 41(2014), 5 vom: 01. Mai, Seite 1000-4 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Tugwell, Peter [VerfasserIn] |
---|
Links: |
---|
Themen: |
CONSTRUCT VALIDITY |
---|
Anmerkungen: |
Date Completed 04.02.2015 Date Revised 31.03.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.3899/jrheum.131310 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM23698442X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM23698442X | ||
003 | DE-627 | ||
005 | 20231224110715.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2014 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3899/jrheum.131310 |2 doi | |
028 | 5 | 2 | |a pubmed24n0790.xml |
035 | |a (DE-627)NLM23698442X | ||
035 | |a (NLM)24692531 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Tugwell, Peter |e verfasserin |4 aut | |
245 | 1 | 0 | |a Updating the OMERACT filter |b implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity |
264 | 1 | |c 2014 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 04.02.2015 | ||
500 | |a Date Revised 31.03.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) Filter provides guidelines for the development and validation of outcome measures for use in clinical research. The "Truth" section of the OMERACT Filter requires that criteria be met to demonstrate that the outcome instrument meets the criteria for content, face, and construct validity | ||
520 | |a METHODS: Discussion groups critically reviewed a variety of ways in which case studies of current OMERACT Working Groups complied with the Truth component of the Filter and what issues remained to be resolved | ||
520 | |a RESULTS: The case studies showed that there is broad agreement on criteria for meeting the Truth criteria through demonstration of content, face, and construct validity; however, several issues were identified that the Filter Working Group will need to address | ||
520 | |a CONCLUSION: These issues will require resolution to reach consensus on how Truth will be assessed for the proposed Filter 2.0 framework, for instruments to be endorsed by OMERACT | ||
650 | 4 | |a Consensus Development Conference | |
650 | 4 | |a Journal Article | |
650 | 4 | |a CONSTRUCT VALIDITY | |
650 | 4 | |a CONTENT VALIDITY | |
650 | 4 | |a FACE VALIDITY | |
650 | 4 | |a OMERACT | |
650 | 4 | |a OUTCOME AND PROCESS ASSESSMENT | |
650 | 4 | |a RANDOMIZED CONTROLLED TRIALS | |
700 | 1 | |a Boers, Maarten |e verfasserin |4 aut | |
700 | 1 | |a D'Agostino, Maria-Antonietta |e verfasserin |4 aut | |
700 | 1 | |a Beaton, Dorcas |e verfasserin |4 aut | |
700 | 1 | |a Boonen, Annelies |e verfasserin |4 aut | |
700 | 1 | |a Bingham, Clifton O |c 3rd |e verfasserin |4 aut | |
700 | 1 | |a Choy, Ernest |e verfasserin |4 aut | |
700 | 1 | |a Conaghan, Philip G |e verfasserin |4 aut | |
700 | 1 | |a Dougados, Maxime |e verfasserin |4 aut | |
700 | 1 | |a Duarte, Catia |e verfasserin |4 aut | |
700 | 1 | |a Furst, Daniel E |e verfasserin |4 aut | |
700 | 1 | |a Guillemin, Francis |e verfasserin |4 aut | |
700 | 1 | |a Gossec, Laure |e verfasserin |4 aut | |
700 | 1 | |a Heiberg, Turid |e verfasserin |4 aut | |
700 | 1 | |a van der Heijde, Désirée M |e verfasserin |4 aut | |
700 | 1 | |a Hewlett, Sarah |e verfasserin |4 aut | |
700 | 1 | |a Kirwan, John R |e verfasserin |4 aut | |
700 | 1 | |a Kvien, Tore K |e verfasserin |4 aut | |
700 | 1 | |a Landewé, Robert B |e verfasserin |4 aut | |
700 | 1 | |a Mease, Philip J |e verfasserin |4 aut | |
700 | 1 | |a Østergaard, Mikkel |e verfasserin |4 aut | |
700 | 1 | |a Simon, Lee |e verfasserin |4 aut | |
700 | 1 | |a Singh, Jasvinder A |e verfasserin |4 aut | |
700 | 1 | |a Strand, Vibeke |e verfasserin |4 aut | |
700 | 1 | |a Wells, George |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t The Journal of rheumatology |d 1983 |g 41(2014), 5 vom: 01. Mai, Seite 1000-4 |w (DE-627)NLM000019593 |x 1499-2752 |7 nnns |
773 | 1 | 8 | |g volume:41 |g year:2014 |g number:5 |g day:01 |g month:05 |g pages:1000-4 |
856 | 4 | 0 | |u http://dx.doi.org/10.3899/jrheum.131310 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 41 |j 2014 |e 5 |b 01 |c 05 |h 1000-4 |